​

Hoth Therapeutics (HOTH) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

HOTH Stock Rating

Hoth Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

HOTH Price Target Upside V Benchmarks

TypeNameUpside
StockHoth Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.42$1.42$1.42
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2511---2
May, 2511---2
Apr, 2511---2
Mar, 2511---2
Feb, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025CitigroupBuyBuyhold
Oct 16, 2024H.C. WainwrightBuyBuyhold
Oct 11, 2024BenchmarkSpeculative BuySpeculative Buyhold
Apr 02, 2024EF HuttonBuyBuyhold
Sep 14, 2023EF HuttonBuyBuyhold
Dec 30, 2022EF HuttonBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.30$-1.28----
Avg Forecast$-2.51$-1.36$-0.68$-0.46$-0.52$-0.82
High Forecast$-2.51$-1.36$-0.68$-0.46$-0.52$-0.82
Low Forecast$-2.51$-1.36$-0.68$-0.46$-0.52$-0.82
Surprise %-8.37%-5.88%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$177.52M---
High Forecast--$177.52M---
Low Forecast--$177.52M---
Surprise %------

Net Income Forecast

$-9M $-8M $-6M $-5M $-3M $-2M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.85M$-8.19M----
Avg Forecast$-8.54M$-4.64M$-2.32M$-1.57M$-1.77M$-2.80M
High Forecast$-8.54M$-4.64M$-2.32M$-1.57M$-1.77M$-2.80M
Low Forecast$-8.54M$-4.64M$-2.32M$-1.57M$-1.77M$-2.80M
Surprise %-8.13%76.61%----

HOTH Forecast FAQ

Is Hoth Therapeutics stock a buy?

Hoth Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Hoth Therapeutics is a favorable investment for most analysts.

What is Hoth Therapeutics's price target?

Hoth Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.42.

How does Hoth Therapeutics stock forecast compare to its benchmarks?

Hoth Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Hoth Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Hoth Therapeutics’s EPS forecast?

Hoth Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.68, marking a -46.88% decrease from the reported $-1.28 in 2024. Estimates for the following years are $-0.46 in 2026, $-0.52 in 2027, and $-0.82 in 2028.

What is Hoth Therapeutics’s revenue forecast?

Hoth Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $177.52M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, and $0 for 2028.

What is Hoth Therapeutics’s net income forecast?

Hoth Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-2.318M, representing a -71.69% decrease from the reported $-8.188M in 2024. Projections indicate $-1.568M in 2026, $-1.773M in 2027, and $-2.796M in 2028.